Serous Adenocarcinoma of Fallopian Tubes: Histological and Immunohistochemical Aspects.
Carcinoma, serous
Estrogen receptor
Fallopian tubes
HER2/neu
Ki-67
Neoplasms
Progesterone receptor
Journal
Journal of pathology and translational medicine
ISSN: 2383-7837
Titre abrégé: J Pathol Transl Med
Pays: Korea (South)
ID NLM: 101650151
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
16
01
2019
accepted:
20
03
2019
pubmed:
12
4
2019
medline:
12
4
2019
entrez:
12
4
2019
Statut:
ppublish
Résumé
Although primary cancer of the fallopian tubes is a relatively rare type of tumor in female reproductive organs, its mortality is quite high. It is important to identify molecular and biological markers of this malignancy that determine its specific phenotype. The study was carried out on samples received from 71 female patients with primary cancer of the fallopian tubes. The main molecular and biological properties, including hormone status (estrogen receptor [ER], progesterone receptor [PR]), human epidermal growth factor receptor (HER2)/neu expression, proliferative potential (Ki-67), apoptosis (p53, Bcl-2), and pro-angiogenic (vascular endothelial growth factor) quality of serous tumors were studied in comparison with clinical and morphological characteristics. ER and PR expression is accompanied by low grade neoplasia, early clinical disease stage, and absence of lymphogenic metastasis (p < .001). HER2/neu expression is not typical for primary cancer of the fallopian tubes. Ki-67 expression is characterized by an inverse correlation with ER and PR (p < .05) and is associated with lymphogenic metastasis (p < .01). p53+ status correlates with high grade malignancy, tumor progression, metastasis, negative ER/PR (p < .001), and negative Bcl-2 status (p < .05). Positive Bcl-2 status is positively correlated with ER and PR expression and low grade malignancy. Complex morphologic (histological and immunohistochemical) study of postoperative material allows estimation of the degree of malignancy and tumor spread to enable appropriate treatment for each case.
Sections du résumé
BACKGROUND
BACKGROUND
Although primary cancer of the fallopian tubes is a relatively rare type of tumor in female reproductive organs, its mortality is quite high. It is important to identify molecular and biological markers of this malignancy that determine its specific phenotype.
METHODS
METHODS
The study was carried out on samples received from 71 female patients with primary cancer of the fallopian tubes. The main molecular and biological properties, including hormone status (estrogen receptor [ER], progesterone receptor [PR]), human epidermal growth factor receptor (HER2)/neu expression, proliferative potential (Ki-67), apoptosis (p53, Bcl-2), and pro-angiogenic (vascular endothelial growth factor) quality of serous tumors were studied in comparison with clinical and morphological characteristics.
RESULTS
RESULTS
ER and PR expression is accompanied by low grade neoplasia, early clinical disease stage, and absence of lymphogenic metastasis (p < .001). HER2/neu expression is not typical for primary cancer of the fallopian tubes. Ki-67 expression is characterized by an inverse correlation with ER and PR (p < .05) and is associated with lymphogenic metastasis (p < .01). p53+ status correlates with high grade malignancy, tumor progression, metastasis, negative ER/PR (p < .001), and negative Bcl-2 status (p < .05). Positive Bcl-2 status is positively correlated with ER and PR expression and low grade malignancy.
CONCLUSIONS
CONCLUSIONS
Complex morphologic (histological and immunohistochemical) study of postoperative material allows estimation of the degree of malignancy and tumor spread to enable appropriate treatment for each case.
Identifiants
pubmed: 30971070
pii: jptm.2019.03.21
doi: 10.4132/jptm.2019.03.21
pmc: PMC6639703
doi:
Types de publication
Journal Article
Langues
eng
Pagination
236-243Références
Gynecol Obstet Invest. 2000;49(1):47-51
pubmed: 10629373
Eur J Gynaecol Oncol. 2000;21(4):364-7
pubmed: 11055483
Int J Cancer. 2003 May 1;104(5):643-5
pubmed: 12594821
Oncology. 2005;69 Suppl 3:4-10
pubmed: 16301830
Eur J Gynaecol Oncol. 2006;27(1):16-8
pubmed: 16550961
J Clin Oncol. 2007 Sep 1;25(25):3985-90
pubmed: 17761984
Acta Obstet Gynecol Scand. 2007;86(12):1419-26
pubmed: 18027113
Gynecol Oncol. 2009 Oct;115(1):97-101
pubmed: 19615725
Cell. 2010 Jan 22;140(2):268-79
pubmed: 20141840
Br J Cancer. 2010 Aug 24;103(5):668-75
pubmed: 20664598
Am J Surg Pathol. 2010 Oct;34(10):1407-16
pubmed: 20861711
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Nat Rev Cancer. 2011 Jul 22;11(8):597-608
pubmed: 21779010
Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3921-6
pubmed: 22331912
Cancer. 1990 Dec 15;66(12):2661-7
pubmed: 2249208
Int J Mol Sci. 2013 Mar 25;14(4):6571-96
pubmed: 23528888
Eur J Obstet Gynecol Reprod Biol. 2013 Jul;169(2):155-61
pubmed: 23622731
J Med Case Rep. 2013 Nov 07;7:252
pubmed: 24199600
J Obstet Gynaecol Can. 2014 Feb;36(2):133-140
pubmed: 24518912
J Hematol Oncol. 2014 Jul 12;7:49
pubmed: 25014991
Eur J Gynaecol Oncol. 2014;35(5):595-6
pubmed: 25423713
Diagn Pathol. 2015 Jun 26;10:79
pubmed: 26112049
Am J Transl Res. 2015 Oct 15;7(10):2082-90
pubmed: 26692952
Georgian Med News. 2016 Dec;(261):68-73
pubmed: 28132046
Pathol Res Pract. 2017 May;213(5):574-579
pubmed: 28214212
Georgian Med News. 2017 Sep;(270):10-15
pubmed: 28972476
Georgian Med News. 2017 Oct;(271):12-17
pubmed: 29099694
Cancer. 1995 Jun 15;75(12):2891-6
pubmed: 7773939
Gynecol Oncol. 1994 Jun;53(3):307-13
pubmed: 8206403